As a novel inhibitor of GP130/STAT3 signaling, Bazedoxifene could suppress pancreatic cancer growth in vitro and in vivo and sensitize pancreatic cancer cells to paclitaxel and gemcitabine [45]. This evidence concerns the gene STAT3 and familial pancreatic carcinoma.